AU7360700A - Methods and compositions for preventing and treating urinary tract disorders - Google Patents
Methods and compositions for preventing and treating urinary tract disordersInfo
- Publication number
- AU7360700A AU7360700A AU73607/00A AU7360700A AU7360700A AU 7360700 A AU7360700 A AU 7360700A AU 73607/00 A AU73607/00 A AU 73607/00A AU 7360700 A AU7360700 A AU 7360700A AU 7360700 A AU7360700 A AU 7360700A
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- preventing
- methods
- urinary tract
- treating urinary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/08—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15290299P | 1999-09-09 | 1999-09-09 | |
US60152902 | 1999-09-09 | ||
PCT/US2000/024685 WO2001017480A2 (en) | 1999-09-09 | 2000-09-08 | Methods and compositions for preventing and treating urinary tract disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU7360700A true AU7360700A (en) | 2001-04-10 |
Family
ID=22544943
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU73607/00A Abandoned AU7360700A (en) | 1999-09-09 | 2000-09-08 | Methods and compositions for preventing and treating urinary tract disorders |
AU73600/00A Abandoned AU7360000A (en) | 1999-09-09 | 2000-09-08 | Methods and compositions for preventing and treating prostate disorders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU73600/00A Abandoned AU7360000A (en) | 1999-09-09 | 2000-09-08 | Methods and compositions for preventing and treating prostate disorders |
Country Status (3)
Country | Link |
---|---|
EP (2) | EP1214038A2 (en) |
AU (2) | AU7360700A (en) |
WO (2) | WO2001017479A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020099003A1 (en) | 1997-10-28 | 2002-07-25 | Wilson Leland F. | Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof |
GB0029903D0 (en) * | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
DE10103262A1 (en) * | 2001-01-25 | 2002-08-01 | Axel Schmidt-Dossi | Suppository containing oxybutynin, useful for treatment of incontinence, avoids side effects and allows an increase in dose |
TWI301164B (en) | 2001-10-12 | 2008-09-21 | Phild Co Ltd | |
FR2850864B1 (en) * | 2003-02-12 | 2007-04-13 | Oreal | USE OF A 15-HYDROXY PROSTAGLANDIN DEHYDROGENASE INHIBITOR TO PROMOTE PIGMENTATION OF SKIN OR PHANES |
EP1594438B1 (en) | 2003-02-12 | 2013-07-17 | L'Oréal | Use of an inhibitor of 15-hydroxyprostaglandin dehydrogenase in order to stimulate pigmentation of the skin or hair |
DE602004020337D1 (en) * | 2004-08-11 | 2009-05-14 | Boehringer Ingelheim Pharma | Anticholinergic drugs for the treatment of urinary tract disorders |
US20090186896A1 (en) * | 2005-09-29 | 2009-07-23 | Bayer Healthcare Ag | PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders |
US7902260B2 (en) * | 2007-02-28 | 2011-03-08 | Kemphys Ltd. | Medicament for preventive and/or therapeutic treatment of lower urinary tract symptom |
US9415048B2 (en) | 2010-07-08 | 2016-08-16 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US10278925B2 (en) | 2012-01-04 | 2019-05-07 | Wellesley Pharmaceuticals, Llc | Delayed-release formulations, methods of making and use thereof |
CA2856673C (en) | 2012-01-04 | 2018-08-21 | Wellesley Pharmaceuticals, Llc | Use of acetaminophen for reducing the frequency of urination |
KR20150048741A (en) * | 2012-07-27 | 2015-05-07 | 웰즐리 파마슈티컬스 엘엘씨 | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US10945998B2 (en) * | 2015-03-08 | 2021-03-16 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating fibrosis |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
KR20230012471A (en) | 2020-03-30 | 2023-01-26 | 트리젤 엘티디. | Compositions and methods for treating cancer |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3171774D1 (en) * | 1980-03-31 | 1985-09-19 | Teijin Ltd | Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom |
US4474813A (en) * | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
SU1130345A1 (en) * | 1981-12-10 | 1984-12-23 | Киевский Научно-Исследовательский Институт Заболеваний Почек И Мочевыводящих Путей /Урологии/ | Method of treatment of chronic urethroprostatitis |
DE3408260A1 (en) * | 1984-03-07 | 1985-09-26 | Roshdy Dipl.-Chem. Dr. 5000 Köln Ismail | Suppositories containing vitamin E |
US5085650A (en) * | 1989-10-20 | 1992-02-04 | Giglio Frank A | Gynecological urethral suppository |
CN1030687C (en) * | 1989-11-17 | 1996-01-17 | 沈阳铁路局中心医院 | Preparation of medicine applied on urethra |
RU2024253C1 (en) * | 1991-03-27 | 1994-12-15 | Валентина Васильевна Малиновская | Rectal suppositories and device for introduction thereof |
GB2260902A (en) * | 1991-09-12 | 1993-05-05 | Eurocetus Bv | Interleukin-2 and tumour necrosis factor for treating bladder cancer |
US5598549A (en) * | 1993-06-11 | 1997-01-28 | At&T Global Information Solutions Company | Array storage system for returning an I/O complete signal to a virtual I/O daemon that is separated from software array driver and physical device driver |
US5480640A (en) * | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
DE19529102A1 (en) * | 1995-08-08 | 1997-02-13 | Kummer Horst Dieter | Use of PDE inhibitors in the treatment of bladder disorders |
WO1997010842A1 (en) * | 1995-09-19 | 1997-03-27 | Schering Aktiengesellschaft | COMBINATION OF β-INTERFERON FOR THE TREATMENT OF PROSTATE CANCER |
DE19540642A1 (en) * | 1995-11-01 | 1997-05-07 | Stief Christian Georg Priv Doz | Use of phosphodiesterase I, IV and V inhibitors |
US5877215A (en) * | 1996-03-20 | 1999-03-02 | Medical University Of South Carolina | Method of treating neoplastic cells with prostaglandin and radiation treatment or prostaglandin and platinum-based anti-tumor agents |
JP2001507696A (en) * | 1996-12-31 | 2001-06-12 | アンチオキシダント ファーマシューティカルズ コーポレーション | Pharmaceutical formulation of glutathione and method of administration thereof |
CA2295595A1 (en) * | 1997-07-09 | 1999-01-21 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
US6630515B2 (en) * | 1997-08-28 | 2003-10-07 | Afferon Corporation | Urinary incontinence therapy |
DE19739693A1 (en) * | 1997-09-04 | 1999-03-11 | Schering Ag | Synergistic treatment of multiple sclerosis and other neurodegenerative disorders |
WO1999056739A1 (en) * | 1998-05-07 | 1999-11-11 | The University Of Tennessee Research Corporation | A method for chemoprevention of prostate cancer |
-
2000
- 2000-09-08 AU AU73607/00A patent/AU7360700A/en not_active Abandoned
- 2000-09-08 WO PCT/US2000/024676 patent/WO2001017479A2/en not_active Application Discontinuation
- 2000-09-08 EP EP00961680A patent/EP1214038A2/en not_active Withdrawn
- 2000-09-08 EP EP00961687A patent/EP1214039A2/en not_active Withdrawn
- 2000-09-08 WO PCT/US2000/024685 patent/WO2001017480A2/en not_active Application Discontinuation
- 2000-09-08 AU AU73600/00A patent/AU7360000A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU7360000A (en) | 2001-04-10 |
EP1214038A2 (en) | 2002-06-19 |
WO2001017480A2 (en) | 2001-03-15 |
WO2001017480A3 (en) | 2001-11-01 |
EP1214039A2 (en) | 2002-06-19 |
WO2001017479A3 (en) | 2001-09-20 |
WO2001017479A2 (en) | 2001-03-15 |
WO2001017479B1 (en) | 2002-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001275257A1 (en) | Methods and devices for the treatment of urinary incontinence | |
AU8003800A (en) | Methods and compositions for treating neurobehavioral disorders | |
AU5598300A (en) | Non-invasive and minimally invasive methods and devices for treating urinary incontinence or obstruction | |
EP1143956A3 (en) | Compositions and methods for the treatment of anorectal disorders | |
AU2002219945A1 (en) | Composition and method for treating snoring | |
AU7360700A (en) | Methods and compositions for preventing and treating urinary tract disorders | |
AU5309400A (en) | Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives | |
AU3877900A (en) | Compositions and methods for preventing and treating sexual dysfunctions | |
AU5601300A (en) | Method and compositions for treating and preventing retinal damage | |
AU2002236626A1 (en) | Compositions and methods for treating hyperpigmentation | |
AU5838700A (en) | Method for treating and preventing finger disorders | |
AU2002237667A1 (en) | Methods for the treatment and prevention of urinary stone disease | |
AU2002235692A1 (en) | Methods and compositions for preventing and treating neutrophil-mediated diseases | |
AU4033900A (en) | Compositions and methods for treating cell proliferation disorders | |
WO2003039490A9 (en) | Compositions and methods for diagnosing and treating mental disorders | |
AUPQ968700A0 (en) | Treatment of urinary incontinence | |
AU1953701A (en) | Methods and compositions for treatment of inflammatory disease | |
AU4515001A (en) | Compositions and methods for locally treating inflammatory diseases | |
AU2001232345A1 (en) | Compositions for preventing and treating digestive diseases | |
AU2001238288A1 (en) | Method and compositions for treating fibrotic diseases | |
AU1196601A (en) | Methods of diagnosing and treating urinary incontinence | |
AUPQ872800A0 (en) | Compositions and methods for treating cardiovascular disorders | |
AU1166000A (en) | 1-aminoethylquinoline derivatives for treating urinary incontinence | |
AU2002217915A1 (en) | Compositions and methods for diagnosing or treating psoriasis | |
AU5169200A (en) | Methods and compositions for treating breakthrough pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |